MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/aor.14942

Медицинская библиотека · Artificial organs · 2025

Glucagon-Like Peptide-1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices.

Elad Boaz, Lee Changhee, Rahman Afsana, Rzechorzek Wojciech, DeFilippis Ersilia M, Lotan Dor, Moeller Cathrine M, Valledor Andrea Fernandez, Rahman Salwa, Baranowska Julia, Clerkin Kevin, Fried Justin, Yunis Adil, Yuzefpolskaya Melana, Colombo Paolo C, Kaku Yuji, Naka Yoshifumi, Takeda Koji, Raikhelkar Jayant, Sayer Gabriel T, Uriel Nir

СтатьяПеревод в очереди

Аннотация

BACKGROUND

GLP-1 RAs improve cardiometabolic outcomes in obese, diabetic, and heart failure patients. Data on the safety and efficacy of GLP-1 RA in advanced heart failure with durable LVAD is limited.

OBJECTIVES

To assess the safety and efficacy of GLP-1 RA in durable LVAD patients.

METHODS

We conducted a single-center retrospective analysis of patients on durable LVAD support treated with GLP-1 RA. Outcomes included cardiometabolic efficacy and LVAD and GLP-1 RA related adverse events up to 1 year post GLP-1 RA initiation.

RESULTS

Forty LVAD patients were treated with GLP-1 RA therapy between 2018 and 2023. At 1 year follow-up, the patient's weight was significantly reduced (116 (98-134) vs. 110 (91-129) kg, p-value < 0.001), HBA1C was improved (6.4 (5.8-8.1) vs. 5.7 (5.3-6.1), p-value 0.003), and NT-proBNP levels were significantly reduced (810 (594-1413) vs. 732 (354-1155) pg/mL, p-value 0.04). GLP-1 RA therapy was not associated with cannula position change (cannula coronal angle of 29.7° (15.0-42.0) vs. 23.1° (12.8-42.3), p-value 0.683), and LVADs complication rate was relatively low (12.5% of the patients had hemocompatibility adverse events, 15% had driveline infection, 12% had HF hospitalization, and 2.5% (1 patient) died due to HeartMate2 malfunction). There was no interruption of drug administration due to adverse events.

CONCLUSION

Durable LVAD patients treated with GLP-1 RA had improved cardiometabolic profiles and low major adverse events. GLP-1 RA therapy holds promise as a potential adjunctive treatment strategy in LVAD recipients, offering improved cardiometabolic profile, hemodynamics, and potential future transplant candidacy.

Для цитирования: Elad Boaz, Lee Changhee, Rahman Afsana, Rzechorzek Wojciech, DeFilippis Ersilia M, Lotan Dor, Moeller Cathrine M, Valledor Andrea Fernandez, Rahman Salwa, Baranowska Julia, Clerkin Kevin, Fried Justin, Yunis Adil, Yuzefpolskaya Melana, Colombo Paolo C, Kaku Yuji, Naka Yoshifumi, Takeda Koji, Raikhelkar Jayant, Sayer Gabriel T, Uriel Nir. Glucagon-Like Peptide-1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices.. Artificial organs. 2025. DOI: 10.1111/aor.14942.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.